Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_assertion type Assertion NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_head.
- NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_assertion description "[The efficacy of LPZ (15 mg/day) as maintenance therapy for erosive RE is influenced by CYP2C19 polymorphism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_provenance.
- NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_assertion evidence source_evidence_literature NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_provenance.
- NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_assertion SIO_000772 17295875 NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_provenance.
- NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_assertion wasDerivedFrom gad-20150221 NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_provenance.
- NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_assertion wasGeneratedBy ECO_0000203 NP55113.RAVvbakre5DYTK7A1XasKXaafEN8nJW3j_Dy5C0LPwwSA130_provenance.